Drugs / CIMAvax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02955290 | Dec 2016 → May 2025 overdue | head and neck squamous cell carcinoma, non-small cell squamous lung carcinoma | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CIMAvax | “EGF Vaccine CIMAvax” NCT02955290 ↗ |
| Modality | Vaccine | “EGF Vaccine CIMAvax” NCT02955290 ↗ |
| Route | Intramuscular | “Given CIMAvax IM” NCT02955290 ↗ |